quinazolines has been researched along with Astrocytoma, Grade IV in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.43) | 18.2507 |
| 2000's | 64 (30.48) | 29.6817 |
| 2010's | 135 (64.29) | 24.3611 |
| 2020's | 8 (3.81) | 2.80 |
| Authors | Studies |
|---|---|
| Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Irani, S; Kashani, B; Momeny, M; Mousavi, SA; Shamsaiegahkani, S; Yousefi, H | 1 |
| Alfred Yung, WK; Ding, J; Gao, F; Khan, S; Koul, D; Li, X; Lozano, G; Sen, S; Wasylishen, AR; Zhang, C; Zhao, Y | 1 |
| Chen, S; Li, D; Li, J; Liu, Q; Wang, L; Zhao, J | 1 |
| Christou, YA; Dietis, N; Georgiades, SN; Ilmi, R; Odysseos, AD; Pitris, C; Stylianou, P; Tseriotou, E; Ttofi, I | 1 |
| Abdulkarim, B; Daniel, P; Duncan, HM; Eppert, K; Guiot, MC; Jean-Claude, B; Lauzon, N; Meehan, B; Petrecca, K; Rak, J; Sabri, S; Schmitt, J; Sharifi, Z | 1 |
| Crish, JF; Elmquist, WF; Gampa, G; Hinojosa, AQ; Kenchappa, RS; Kim, M; Luu, A; Mohammad, AS; Parrish, KE; Rosenfeld, SS; Sarkaria, JN; West, R | 1 |
| Hanna, J; Li, Y; Orahoske, CM; Petty, A; Salem, FM; Su, B; Wang, B; Zhang, W | 1 |
| Bambini, V; Brunetto, AT; de Farias, CB; Freire, NH; Jaeger, M; Metcalfe, VA; Pinheiro, KV; Roesler, R; Shaw, L; Smith, CGS; Souza, BK; Thomaz, A | 1 |
| Hao, GF; Huang, W; Ming, ZH; Tian, YG; Wang, MS; Wu, FX; Xu, HC; Yang, FP; Zhao, XE; Zhu, XL; Zhuo, LS | 1 |
| Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ | 1 |
| Camphausen, K; Kil, WJ; Kramp, TR; Lee, J; Tofilon, PJ; Yun, HS | 1 |
| Breunig, JJ; Chan, SL; Chen, Y; Ching, J; Ding, LW; Doan, N; Dutra-Clarke, M; Hazawa, M; Jiang, YY; Koeffler, HP; Kovalik, JP; Lin, DC; Madan, V; Mayakonda, A; Müschen, M; Said, JW; Savinoff, SE; Tyner, JW; Watkins, A; Xu, L; Yang, H; Yong, WH | 1 |
| Goswami, D; Goyal, S; Grover, A; Jain, R; Jamal, S; Wahi, D | 1 |
| Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M | 1 |
| Chen, YC; Chien, CC; Chiu, WT; Liu, KH; Wu, WS | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Doh, I; Lee, DW; Lee, SY; Nam, DH; Ryu, GH | 1 |
| Haeno, H; Michor, F; Stein, S; Vivanco, I; Zhao, R | 1 |
| Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D | 1 |
| Harter, PN; Mittelbronn, M; Pietsch, T; Reuter, D; Ronellenfitsch, MW; Senft, C; Steinbach, JP; Urban, H; Westphal, M; Zeiner, PS | 1 |
| Lin, M; Yao, Z; Zhang, C; Zhao, N | 1 |
| Chern, JW; Hsin, LW; Hung, PY; Liu, JR; Yu, CW | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Han, S; He, QH; Li, P; Liu, KY; Liu, XJ; Liu, XX; Liu, YN; Ma, SH; Qin, JZ; Shen, L; Wu, WH; Wu, WT; Yin, F; Zhang, JM; Zhang, XY | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Beriwal, S; Flickinger, JC; Vargo, JA | 1 |
| Batchelor, TT; de Groot, J; Reardon, DA | 1 |
| Carrillo, V; Dubisz, E; Gulzar, H; Mahajan, SS; Morgan, D; Yelskaya, Z | 1 |
| Canoll, P; Dionne, KR; Foreman, NK; Klaassen, M; Kleinschmidt-Demasters, BK; Massarwa, R; Niswander, L; Parker, JJ; Waziri, A | 1 |
| Chen, KC; Chiu, WT; Hou, SY; Hsiao, SH; Kuei, HP; Liu, AJ; Shih, CM; Shih, YL; Wang, SH | 1 |
| Alafuzoff, I; Bergqvist, M; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, F; Lennartsson, J; Navani, S; Pontén, F; Popova, S; Sooman, L; Tsakonas, G | 1 |
| Gallo, JM; Lv, H; Sharma, J | 2 |
| Fang, W; Li, A; Luo, S; Niu, X; Ruan, J; Shen, J; Tian, G; Zhao, P; Zheng, H | 1 |
| Bachem, MG; Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR; Zhou, S | 1 |
| Kathagen, A; Kolbe, K; Lamszus, K; Liffers, K; Merlo, A; Riethdorf, S; Schulte, A; Westphal, M; Zapf, S | 1 |
| Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J | 1 |
| Batchelor, TT; Bjornerud, A; Borra, RJ; Emblem, KE; Farrar, CT; Ivy, P; Jain, RK; Jennings, D; Mouridsen, K; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Chen, Y; Fisher, CJ; Kuta, V; Lai, B; Lilge, LD; Niu, CJ | 1 |
| Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Ancukiewicz, M; Batchelor, TT; Chi, AS; Dietrich, J; Duda, DG; Eichler, AF; Emblem, KE; Gerstner, ER; Hochberg, FH; Iafrate, AJ; Ivy, SP; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Loeffler, JS; Lu-Emerson, C; Pinho, MC; Plotkin, SR; Polaskova, P; Rosen, BR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Cavenee, WK; Cloughesy, TF; Eskin, A; Furnari, FB; Gini, B; Gomez, G; Heath, JR; Hwang, K; James, CD; Koga, T; Kornblum, HI; Masui, K; Mischel, PS; Mottahedeh, J; Nathanson, DA; Nelson, SF; Ohashi, M; Paucar, A; Rao, PN; Reed, R; Visnyei, K; Wang, J; Wykosky, J; Yang, H; Zhu, S | 1 |
| Homicsko, K; Hottinger, AF; Stupp, R | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Chamberlain, MC; Fadul, CE; Grimm, S; Kim, L; Phuphanich, S; Recht, L; Rosenfeld, S; Zhu, JZ | 1 |
| Addeo, R; Caraglia, M; Parlato, C; Zappavigna, S | 1 |
| Han, D; Sun, J; Wang, F; Xiao, W; Zhu, Y | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Ladizinski, B; Sankey, C | 1 |
| Buonato, JM; Furcht, CM; Lazzara, MJ; Mathew, LK; Muñoz Rojas, AR; Simon, MC; Skuli, N | 1 |
| Aldape, K; Berens, ME; Carrera-Silva, EA; Dietrich, JD; Errasti, AE; Ghosh, S; Gibbs, D; Hulme, C; Kusne, Y; Loftus, JC; Lu, Z; Mandell, EK; Perry, AS; Rothlin, CV; Rushing, EJ; Sanai, N; Yang, W | 1 |
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Carlomagno, C; Della Vittoria Scarpati, G; Ferrone, S; Fusciello, C; Leonardi, A; Pacelli, R; Pepe, S; Pepin, D; Poudel, R; Sabbatino, F; Somma, D | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Bi, Y; Fan, L; Gao, H; Khan, M; Qazi, JI | 1 |
| Cavenee, WK; Furnari, FB; Gonias, SL; Hu, J; Muller, KA; VandenBerg, SR | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Perek, N; Prevot, N; Puech, C | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Batchelor, TT; Beroukhim, R; Betensky, RA; Chheda, MG; Chi, AS; Drappatz, J; Eichler, AF; Gerstner, ER; Hochberg, FH; Norden, AD; Wen, PY; Yang, D | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Pacaud, R; Vallette, FM | 1 |
| Hara, A; Iwama, T; Kunisada, T; Park, DM; Soeda, A; Yoshimura, S | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q | 1 |
| Batchelor, TT; Duda, DG; Emblem, KE; Gerstner, ER; Jain, RK; Loeffler, JS; Lu-Emerson, C; Taylor, JW | 1 |
| Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET | 1 |
| Aljohani, H; Bahassi, el M; Koncar, RF; Lee, SH; Park, BS; Zarzour, A | 1 |
| Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X | 1 |
| Bronshtein, T; Haber, T; Machluf, M; Shivinsky, A | 1 |
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Dikomey, E; Gal, A; Grob, TJ; Kriegs, M; Lamszus, K; Petersen, C; Rieckmann, T; Riedel, M; Rothkamm, K; Schulte, A; Struve, N | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Amoresano, A; Camorani, S; Carpentieri, A; Cerchia, L; Chiariello, M; Colecchia, D; Crescenzi, E; Fedele, M | 1 |
| Clark, SW; Ma, Y; Mobley, BC; Sarkaria, JN; Tang, N; Thompson, RC; Wang, J | 1 |
| Butman, JA; Fine, HA; Iwamoto, FM; Kreisl, TN; Odia, Y; Shih, JH; Sul, J | 1 |
| Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q | 1 |
| Amoozgar, Z; Batchelor, TT; Batista, A; Chatterjee, S; Datta, M; Duda, DG; Farrar, CT; Fukumura, D; Goveia, J; Huang, Y; Jain, RK; Jung, K; Kamoun, WS; Kirkpatrick, ND; Kloepper, J; Leow, CC; Marijt, KA; Muzikansky, A; Peterson, TE; Seano, G; Snuderl, M; Vardam, T; Xu, L | 1 |
| Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V | 1 |
| Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K | 1 |
| Chen, Y; Mu, L; Tang, X; Wang, T; Yuan, Y; Zhao, Y | 1 |
| Batchelor, TT; Chowdhary, S; Desideri, S; Duda, DG; Gerstner, ER; Grossman, S; Lesser, GJ; Peereboom, D; Supko, JG; Wen, PY; Ye, X | 1 |
| Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B | 1 |
| Ciechomska, IA; Jackl, J; Kaminska, B; Przanowski, P; Wojtas, B | 1 |
| Bachoo, RM; Cho, SK; Hatanpaa, KJ; Humphries, CG; Kim, RS; Kittler, R; Klingler, S; Kollipara, RK; Maher, EA; Mashimo, T; Mickey, B; Nannepaga, S; Piccirillo, S; Raisanen, J; Regmi, N; Singh, DK; Sirasanagandla, S; Sun, Y; Vemireddy, V; Wang, S; Yang, XL; Zheng, H | 1 |
| Benveniste, EN; Dees, KJ; Gibson, SA; Hjelmeland, AB; McFarland, BC; Meares, GP; Nozell, SE; Rajbhandari, R; Rowse, AL | 1 |
| Ahmadinia, L; Alimoghaddam, K; Amanpour, S; Barghi, F; Dardaei, L; Dehpour, AR; Emami, AH; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Ghazi-Khansari, M; Gortany, NK; Mirshahvaladi, S; Moghaddaskho, F; Momeny, M; Sabourinejad, Z; Tavangar, SM; Yousefi, H; Zarrinrad, G | 1 |
| Barrett, GM; Cemeus, C; Dimitroulakos, J; Lorimer, IA; Zhao, TT | 1 |
| Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH | 1 |
| Chen, C; Gaspar, LE; Kavanagh, BD; Kleinschmidt-De Masters, BK; McCammon, R; Schwer, AL; Stuhr, K | 1 |
| Abrey, LE; Kreisl, TN; Lassman, AB; Lis, E; Mischel, PS; Rosen, N; Scher, HI; Shaffer, D; Teruya-Feldstein, J | 1 |
| Gui, SB; Li, CZ; Liu, FJ; Sun, ZL; Zhang, YZ | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Feuerhake, F; Halatsch, ME; Hielscher, T; Löw, S; Mursch, K; Schmidt, U; Unterberg, A; Vougioukas, VI | 1 |
| Batchelor, TT; di Tomaso, E; Duda, DG; Duyverman, AM; Farrar, CT; Fukumura, D; Jain, RK; Kamoun, WS; Lacorre, DA; Lahdenranta, J; Ley, CD; Munn, LL; Sorensen, AG | 1 |
| Hart, JR; Vogt, PK | 1 |
| Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M | 1 |
| Gallo, JM; Wang, S; Zhou, Q | 1 |
| Bakker, A; Ferruzzi, P; Ghiron, C; Kremer, A; Lamanna, C; Nievo, M; Rossi, M; Valensin, S | 1 |
| Ancukiewicz, M; Batchelor, TT; Chen, PJ; di Tomaso, E; Duda, DG; Jain, RK; Jennings, D; Lahdenranta, J; Sorensen, AG; Wang, M; Wen, PY; Yeo, P; Zhang, WT | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Cornet, K; Foss, CA; Goodwin, CR; Kim, J; Lal, B; Laterra, J; Muzamil, S; Pomper, MG; Sang, Y | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Batchelor, TT; Dietrich, J; Wang, D | 1 |
| Ayuso-Sacido, A; Boockvar, JA; García-Verdugo, JM; Holland, EC; Kapoor, GS; Kratovac, S; Moliterno, JA; O'Rourke, DM; Roy, NS | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Wachsberger, P; Yan, K; Yu, Y | 1 |
| Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Ali-Osman, F; Cao, X; Keir, S; Lo, HW; Zhu, H | 1 |
| Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Batchelor, TT; Chen, PJ; Gerstner, ER; Jain, RK; Sorensen, G; Wen, PY | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Chea, H; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Eichler, AF; Exarhopoulos, A; Gerstner, E; Hochberg, FH; Ivy, P; Jain, RK; Loeffler, JS; Louis, DN; Moses, MA; Plotkin, SR; Sorensen, AG; Wen, PY | 1 |
| Calles, A; Custodio, A; Pérez-Segura, P | 1 |
| Ballman, KV; Behrens, RJ; Buckner, JC; Dakhill, SR; Flynn, PJ; Giannini, C; Jaeckle, KA; James, CD; Krauss, JC; Schaefer, PL; Scheithauer, BW; Uhm, JH; Wu, W | 1 |
| Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK | 1 |
| Beyene, RT; Bleau, AM; Boockvar, JA; Gursel, DB; Holland, EC; Howard, BM | 1 |
| Bulfone, A; Cominelli, M; De Palma, M; Falini, A; Franzin, A; Galli, R; Mazzoleni, S; Pala, M; Poliani, PL; Politi, LS; Sergi Sergi, L | 1 |
| Berezowska, S; Brockhoff, G; Busch, R; Diermeier-Daucher, S; Duyster, J; Grosu, AL; Schlegel, J | 1 |
| Daroczi, B; Dicker, AP; Lawrence, YR; Liu, Y; Wachsberger, PR; Xu, X | 1 |
| Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
| Andronesi, OC; Auluck, PK; Batchelor, TT; di Tomaso, E; Duda, DG; Fazlollahi, L; Frosch, MP; Hedley-Whyte, ET; Jain, RK; Kamoun, WS; Plotkin, SR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Fine, HA; Floeter, MK; Iwamoto, FM; Kreisl, TN; Lehky, TJ | 1 |
| Carrasco-García, E; Conde, M; Ferragut, JA; García-Morales, P; Gómez-Martínez, A; Grasso, S; Martínez-Lacaci, I; Rocamora-Reverte, L; Saceda, M | 1 |
| Bady, P; Delorenzi, M; Diserens, AC; Frei, K; Hamou, MF; Hegi, ME; Heppner, FL; Hofer, S; Kamoshima, Y; Koch, A; Kouwenhoven, MC; Lambiv, WL; Mariani, L; Matter, MS; Merlo, A; Yonekawa, Y | 1 |
| Batchelor, TT; Bjornerud, A; Borra, RJ; Emblem, KE; Jain, RK; Mouridsen, K; Sorensen, AG | 1 |
| Andronesi, OC; Batchelor, TT; Catana, C; Jain, RK; Jennings, DL; Kim, H; Ratai, EM; Sorensen, AG | 1 |
| Airiau, K; Belaud-Rotureau, MA; Belloc, F; Eimer, S; Jeanneteau, M; Laharanne, E; Loiseau, H; Merlio, JP; Véron, N; Vital, A | 1 |
| Billups, CA; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Maris, JM; Morton, CL; Smith, MA; Wu, J | 1 |
| Ahluwalia, MS; Wen, PY | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE; Westhoff, MA; Wirtz, CR | 1 |
| Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V | 1 |
| Kim, C; Lee, KB; Shah, BP; Subramaniam, P | 1 |
| Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
| Acquaviva, J; Boskovitz, A; Bronson, RT; Charest, A; Donovan, M; Housman, DE; Jun, HJ; Lessard, J; Pfannl, R; Raval, A; Ruiz, R; Whittaker, CA; Woolfenden, S; Zhu, H | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Chao, YS; Cherniack, AD; Chiang, D; Cho, J; Dutt, A; Johnson, W; Kesari, S; Kwon, J; Meyerson, M; Onofrio, RC; Pastorino, S; Vandenberg, S; Verhaak, R; Watanabe, H; Xu, X; Yuza, Y; Zeng, Q | 1 |
| Braoudaki, M; Hatziagapiou, K; Karpusas, M; Tzortzatou-Stathopoulou, F | 1 |
| Akhavan, D; Amzajerdi, AN; Babic, I; Chakravarti, A; Cloughesy, TF; Dang, J; Deangelis, LM; Dejesus, J; Gini, B; Guo, D; Hong, C; Huang, TT; Iwanami, A; James, CD; Kuga, D; Lisiero, DD; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nathanson, D; Prados, MD; Prins, RM; Reinitz, F; Robins, HI; Soto, H; Tanaka, K; Tontonoz, P; Wen, PY; Youssef, M; Zhu, S | 1 |
| Ancukiewicz, M; Batchelor, TT; Emblem, KE; Ivy, P; Jain, RK; Jennings, D; Kim, H; Polaskova, P; Sorensen, AG; Wang, M; Wen, PY | 1 |
| Borges, KS; Brassesco, MS; Carlotti, CG; Castro-Gamero, AM; da Silva Silveira, V; de Oliveira, HF; de Paula Queiroz, RG; Moreno, DA; Scrideli, CA; Tone, LG | 1 |
| Jo, MY; Joo, KM; Kim, HH; Kim, MH; Kim, Y; Kim, YG; Lee, SJ; Nam, DH | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H | 1 |
| Aiken, RD; Akerley, WA; Beelen, AP; Colman, H; De Groot, JF; Evans, BA; Glantz, M; Grossmann, KF; Jensen, RL; Matsuoko, Y; Olsen, JJ; Olson, JJ; Yu, M | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| de Groot, J; Fuller, G; Heimberger, AB; Kong, LY; Liang, J; Piao, Y; Qiao, W; Wei, J | 1 |
| Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
| Airiau, K; Avril, T; Belaud-Rotureau, MA; Belloc, F; Dugay, F; Eimer, S; Quillien, V | 1 |
| Deng, ZL; Dong, YC; Han, QL; Jiang, T; Lv, XH; Ren, H; Xing, WJ; Zou, Y | 1 |
| Cui, K; Hao, A; Jin, G; Liu, Q; Nie, F; Wang, L; Wong, ST; Yao, L; Zhao, H | 1 |
| Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R | 1 |
| Brachman, DG; Bredel, M; Chakravarti, A; Choucair, A; Christiansen, J; Curran, WJ; Dicker, AP; Dolled-Filhart, M; Gustavson, M; Lautenschlaeger, T; Mehta, M; Mischel, P; Molinaro, A; Robins, HI; Schultz, CJ; Wang, M | 1 |
| D'Alessandris, QG; Pallini, R | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Wong, ET; Zhu, JJ | 1 |
| Kapoor, S | 1 |
| Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ | 1 |
| Ambrad, AA; Carey, S; Falsey, R; Glanzberg, H; Kislin, K; Martinez, JD; Meuillet, EJ; Patel, J; Stea, B | 1 |
| Berezin, V; Pedersen, MW; Pedersen, N; Poulsen, HS; Tkach, V | 1 |
| Ochs, JS | 1 |
| A-Borhani, F; Bötefür, IC; Buchfelder, M; Domhof, S; Efferth, T; Gebhart, E; Gehrke, EE; Halatsch, ME; Schmidt, U; Vougioukas, VI | 1 |
| Efferth, T; Gebhart, E; Halatsch, ME; Ramirez, T | 1 |
| Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Hartzell, TL; Learn, CA; Rich, JN; Sampson, JH; Wikstrand, CJ | 1 |
| Aderka, D; Levitt, ML; Pfeffer, MR | 1 |
| Abulrob, A; Andrade, MF; Giuseppin, S; McDermid, A; Moreno, M; Stanimirovic, D | 1 |
| Rasheed, BK; Rich, JN; Yan, H | 1 |
| Carpentier, AF | 1 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Cappuzzo, F | 1 |
| Bigner, DD; Kwatra, MM; Richardson, MD; Yamaguchi, K | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Raben, D; Ryan, A; Tortora, G | 1 |
| Raizer, JJ | 1 |
| Erlichman, C; Goble, JM; James, CD; Lamont, JD; Mladek, AC; Rao, RD; Sarkaria, JN | 1 |
| Bigner, DD; Friedman, HS | 1 |
| Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S | 1 |
| Abrey, LE; Gilbert, MR; Lassman, AB | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Burgess, AW; Doherty, MM; Ellis, AG; Johns, TG; Levitzki, A; McLachlan, G; Murphy, R; Nerrie, M; Nice, EC; Scott, AM; Vitali, A; Walker, F; Webster, LK; Weinstock, J | 1 |
| Frei, K; Hofer, S; Rutz, HP | 1 |
| Ballman, KV; Brown, PD; Carlson, BL; Giannini, C; Grogan, P; Guha, A; James, CD; Kitange, GJ; Pandita, A; Sarkaria, JN; Schroeder, MA | 1 |
| Ballman, KV; Brown, PD; Buckner, JC; Fiveash, JB; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Krishnan, S; Nabors, LB; Uhm, JH | 1 |
| Bernhardt, G; Buschauer, A; Gartner, M; Giannis, A; Gross, D; Müller, C; Sarli, V | 1 |
| Pedersen, MW; Poulsen, HS | 1 |
| Cavenee, WK; Cloughesy, TF; Dia, EQ; Lu, KV; Mellinghoff, IK; Mischel, PS; Sawyers, CL; Shackleford, GM; Vivanco, I; Wang, MY; Zhu, S | 1 |
| Frei, K; Hofer, S | 1 |
| Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P | 1 |
| Beroukhim, R; Cloughesy, T; DeBiasi, RM; Feng, WL; Gabriel, S; Getz, G; Glatt, KA; Greulich, H; Huang, JH; Kawaguchi, T; Khan, H; King, JC; Leahy, DJ; Lee, JC; Levine, RL; Liau, LM; Linhart, DJ; Mellinghoff, IK; Meyerson, M; Mischel, P; Nelson, SF; Nghiemphu, P; O'Neill, K; Onofrio, R; Paez, JG; Peck, TC; Pieper, RO; Rao, PN; Sawyers, CL; Sellers, WR; Thomas, RK; Vivanco, I; Xu, Q; Yoshimoto, K; Yuza, Y; Ziaugra, L | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M | 1 |
| Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF | 1 |
| Carlson, BL; Dinca, EB; Galanis, E; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Sarkaria, JN; Schroeder, MA; Wu, W; Yang, L | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Bradner, JE; Brennan, C; Chin, L; DePinho, RA; Kimmelman, AC; Ligon, KL; Nabioullin, R; Ponugoti, AH; Stegh, AH; Stommel, JM; Wiedemeyer, R; Ying, H | 1 |
| Gallo, JM; Guo, P; Wang, S; Wang, X; Zhou, Q | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Cavenee, WK; Gazit, A; Huang, HJ; Levitzki, A; Nagane, M | 1 |
| Liu, XP; Myers, DE; Narla, RK; Uckun, FM | 1 |
| Klis, D; Liu, XP; Narla, RK; Uckun, FM | 1 |
| Burgess, AW; Cavenee, WK; Huang, HJ; Levitzki, A; Mishima, K; Nagane, M; Narita, Y | 1 |
| Chakravarti, A; Dyson, NJ; Loeffler, JS | 1 |
| Archer, GE; Friedman, HS; Glazer, CA; Lal, A; Martinson, HM; Riggins, GJ; Sampson, JH | 1 |
| Giese, NA; Hollenbach, SJ; Israel, MA; Lokker, NA; Sullivan, CM | 1 |
15 review(s) available for quinazolines and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Disease Progression; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Biological; Myeloid Cells; Neoplasm Proteins; Neovascularization, Pathologic; Patient Selection; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Tumor Microenvironment; Vascular Endothelial Growth Factors | 2013 |
Standards of care and novel approaches in the management of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit | 2014 |
Erlotinib: early clinical development in brain cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2014 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
Erlotinib in glioblastoma: lost in translation?
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
Personalized medicine for glioblastoma: current challenges and future opportunities.
Topics: Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Genetic Variation; Glioblastoma; Humans; Isocitrate Dehydrogenase; MicroRNAs; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment | 2013 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
46 trial(s) available for quinazolines and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal, Humanized; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Calcium-Binding Proteins; Cohort Studies; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; ErbB Receptors; Female; Glioblastoma; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Microfilament Proteins; Necrosis; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6; Signal Transduction; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2018 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; International Agencies; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2013 |
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Blood Vessels; Brain; Glioblastoma; Humans; Magnetic Resonance Angiography; Microcirculation; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Magnetic Resonance Imaging; Oxygen; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Sirolimus | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Piperidines; Quinazolines; Temozolomide; Treatment Outcome | 2015 |
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult | 2015 |
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Quinazolines | 2016 |
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A | 2016 |
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Tissue Distribution; Treatment Outcome | 2017 |
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome | 2008 |
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Tumor Burden; Young Adult | 2009 |
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Gefitinib; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Sirolimus | 2009 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2 | 2010 |
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
Topics: Antineoplastic Agents; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Proportional Hazards Models; Quinazolines | 2010 |
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2010 |
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Enzyme Activators; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Quinazolines; Young Adult | 2011 |
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2010 |
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Young Adult | 2011 |
T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Contrast Media; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Angiography; Male; Quinazolines; Radiography; Survival Rate | 2011 |
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2011 |
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2012 |
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cohort Studies; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2012 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
Topics: Age Factors; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Phase II trial of gefitinib in recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2006 |
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2007 |
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
149 other study(ies) available for quinazolines and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioblastoma; Growth Inhibitors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2021 |
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
Topics: Animals; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Glioblastoma; Glioma; Mice; Pyridazines; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2022 |
Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Glioblastoma; Mice, Inbred BALB C; Mice, Nude; Quinazolines; RNA, Small Interfering; RNAi Therapeutics; STAT3 Transcription Factor | 2019 |
A Novel Conjugate of Bis[((4-bromophenyl)amino)quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex Exhibits Specific Subcellular Localization in Mitochondria.
Topics: Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Extranodal Extension; Fluorescent Dyes; Glioblastoma; Humans; Mitochondria; Protein Kinase Inhibitors; Quinazolines; Ruthenium; Subcellular Fractions | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Blood-Brain Barrier; Brain; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Glioblastoma; Humans; Kinesins; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Quinazolines; Tetrahydroisoquinolines; Xenograft Model Antitumor Assays | 2020 |
Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Dimerization; Doxazosin; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Hydrocarbons, Aromatic; Molecular Structure; Polyethylene Glycols; Protein Binding; Quinazolines; Receptor, EphA2; Structure-Activity Relationship; Substrate Specificity | 2020 |
Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Topics: Animals; Antineoplastic Agents; Azepines; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Receptor, trkB; Tyrphostins; Xenograft Model Antitumor Assays | 2020 |
Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Female; Glioblastoma; Humans; Mice, Nude; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Naphthyridines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Rats; Structure-Activity Relationship; Thermodynamics; Xenograft Model Antitumor Assays | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mutation; Poly (ADP-Ribose) Polymerase-1; PTEN Phosphohydrolase; Quinazolines; Temozolomide; Tumor Suppressor Proteins | 2020 |
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Cycle; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
BCL6 promotes glioma and serves as a therapeutic target.
Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MAP Kinase Kinase Kinases; Mice, Mutant Strains; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
GQSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human Glioblastoma tumors.
Topics: Antineoplastic Agents; Cell Proliferation; Combinatorial Chemistry Techniques; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Quantitative Structure-Activity Relationship; Quinazolines | 2017 |
Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Topics: Aminolevulinic Acid; Astrocytes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Gene Expression; Glioblastoma; Heme Oxygenase-1; Humans; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2017 |
Evodiamine Prevents Glioma Growth, Induces Glioblastoma Cell Apoptosis and Cell Cycle Arrest through JNK Activation.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Survival; Cell Transformation, Neoplastic; Evodia; Glioblastoma; Glioma; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2017 |
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform.
Topics: Antineoplastic Agents; Astrocytes; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Glioblastoma; High-Throughput Screening Assays; Humans; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2017 |
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Lapatinib; Logistic Models; Maximum Tolerated Dose; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmustine; Chemoradiotherapy; Dasatinib; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Photons; Progression-Free Survival; Propensity Score; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Snake Venoms; Supratentorial Neoplasms; Temozolomide; Young Adult | 2018 |
TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway.
Topics: Animals; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Protein Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines | 2019 |
A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
Topics: AC133 Antigen; Adolescent; Adult; Animals; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Drug Resistance; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Immunomagnetic Separation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Peptides; Quinazolines; Real-Time Polymerase Chain Reaction; Stem Cells; Young Adult | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
In regard to Chakravarti et al.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Quinazolines | 2013 |
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Glioblastoma; Glutamic Acid; Humans; Quinazolines; Riluzole; Xanthenes | 2013 |
Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
Topics: Cell Movement; Cell Proliferation; Cohort Studies; ErbB Receptors; Gefitinib; Gene Amplification; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2013 |
Evodiamine, a plant alkaloid, induces calcium/JNK-mediated autophagy and calcium/mitochondria-mediated apoptosis in human glioblastoma cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Calcium; Cell Line, Tumor; Evodia; Glioblastoma; Humans; MAP Kinase Signaling System; Models, Biological; Quinazolines | 2013 |
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Glioblastoma; Humans; Male; Middle Aged; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2013 |
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Cell Line, Tumor; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Survival; Chloroquine; ErbB Receptors; Glioblastoma; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Topics: Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Modulation of PPIX synthesis and accumulation in various normal and glioma cell lines by modification of the cellular signaling and temperature.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cytoplasm; Erlotinib Hydrochloride; Glioblastoma; Humans; Hypothermia, Induced; Mitochondria; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Protoporphyrins; Quinazolines; Rats; Signal Transduction | 2013 |
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Drug Interactions; Gefitinib; Glioblastoma; Humans; Quinazolines; Sertraline; Stilbenes | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Single-Cell Analysis; Tumor Cells, Cultured; Withholding Treatment | 2014 |
MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.
Topics: Blotting, Western; Cell Line, Tumor; Chromones; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Matrix Metalloproteinase 9; MicroRNAs; Models, Genetic; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tyrphostins | 2014 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Indoles; MAP Kinase Signaling System; Mice, Nude; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-met; Quinazolines; STAT3 Transcription Factor; Sulfones | 2014 |
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.
Topics: Animals; Carcinogenesis; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Kaplan-Meier Estimate; Mice; NF-kappa B; Paracrine Communication; Protein Kinase C; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha | 2014 |
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Flow Cytometry; Glioblastoma; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Protein p53 | 2014 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
Topics: Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Glioblastoma; Humans; Quinazolines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2015 |
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Topics: Animals; Brain Neoplasms; Cell Movement; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptors, Urokinase Plasminogen Activator; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Neoplasm Grading; Phosphates; Protein Isoforms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium-Phosphate Cotransporter Proteins, Type III; Tumor Cells, Cultured | 2014 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Male; Middle Aged; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Quinazolines; Temozolomide | 2015 |
The evidence of glioblastoma heterogeneity.
Topics: Animals; Antigens, CD; Brain Neoplasms; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin-Like Growth Factor Binding Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Drug Synergism; Gefitinib; Gene Amplification; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; S Phase | 2015 |
The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Glioblastoma; Glycolates; Humans; Lactic Acid; Male; Mice; Mice, Nude; Microspheres; Polyesters; Polymers; Protein Kinase Inhibitors; Quinazolines; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2015 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Microscopy, Fluorescence; Quinazolines; Radiation Tolerance; Signal Transduction; X-Rays | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunoenzyme Techniques; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Phosphorylation; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2015 |
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin; Insulin-Like Growth Factor I; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors | 2016 |
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glioblastoma; Macrophages; Mice; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic | 2016 |
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |
β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Quinazolines; Sesquiterpenes; Signal Transduction | 2016 |
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome | 2016 |
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.
Topics: Autophagy; Azepines; Brain Neoplasms; Cell Differentiation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glioblastoma; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Neoplastic Stem Cells; Quinazolines; Tumor Cells, Cultured | 2016 |
Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.
Topics: Animals; Astrocytes; Brain; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Grading; Oligodendrocyte Transcription Factor 2; Plasmids; Plicamycin; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; SOXB1 Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Embryo, Mammalian; Enzyme Inhibitors; Female; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthyridines; Neoplastic Stem Cells; Phenazines; Pregnancy; Quinazolines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Topics: Anoikis; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gefitinib; Glioblastoma; Humans; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; PTEN Phosphohydrolase; Quinazolines | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Glioblastoma; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Suppressor Protein p53 | 2008 |
Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression; Genome-Wide Association Study; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Topics: Animals; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Glioblastoma; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2009 |
Akt demoted in glioblastoma.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Maleimides; Models, Biological; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases | 2009 |
Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Quinazolines; Therapeutic Equivalency; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Topics: Animals; Antineoplastic Agents; Astrocytes; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cerebral Cortex; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kinesins; Quinazolines; Rats; Spindle Apparatus | 2009 |
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Antineoplastic Agents; Biomarkers; Blood Volume; Brain Neoplasms; Collagen; Disease-Free Survival; Glioblastoma; Hematologic Tests; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Glioblastoma; Humans; Injections, Intraperitoneal; Kinesins; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, SCID; Osteosarcoma; Quinazolines; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma, Ewing; Single-Blind Method; Spindle Apparatus; Tumor Stem Cell Assay; Wilms Tumor; Xenograft Model Antitumor Assays | 2009 |
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Hepatocyte Growth Factor; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Green Fluorescent Proteins; Humans; Mutation; Nerve Tissue Proteins; Neurons; Oxidative Stress; Quinazolines; Signal Transduction; Stem Cells; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tyrphostins | 2010 |
Acoustic radiation force and optical spectroscopy for assessing tumor vessel normalization during anti-angiogenic therapy.
Topics: Acoustics; Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Cell Line, Tumor; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis; Treatment Outcome | 2009 |
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1 | 2009 |
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Transposable Elements; ErbB Receptors; Female; Gefitinib; Genetic Variation; Glioblastoma; Humans; Mitochondria; Proto-Oncogene Proteins; Quinazolines; Sequence Deletion; Transplantation, Heterologous | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy | 2010 |
EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tyrphostins | 2010 |
Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Gene Silencing; Gene Transfer Techniques; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Quinazolines; RNA, Messenger; Tyrphostins | 2010 |
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Tyrphostins | 2010 |
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Proteins; Piperidines; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Electromyography; Female; Glioblastoma; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Diseases; Neuromuscular Junction; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Syndrome | 2011 |
Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Topics: Blotting, Western; Cell Proliferation; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Glioblastoma; Humans; Immunoprecipitation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2011 |
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Caspases; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; HeLa Cells; Humans; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Signal Transduction | 2011 |
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
Topics: Adolescent; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Glioblastoma; Humans; Infant; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Glioblastoma; Humans; Quinazolines; Treatment Outcome | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay | 2011 |
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat | 2011 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Ligands; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2011 |
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Glioblastoma; Humans; Neuroblastoma; Phosphorylation; Quinazolines; Receptor, ErbB-2 | 2011 |
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Death; Cholesterol; ErbB Receptors; Glioblastoma; HeLa Cells; Humans; Lapatinib; Liver X Receptors; Mice; Mice, SCID; Orphan Nuclear Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2011 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Temozolomide; Time Factors | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Microvessels; Piperidines; Quinazolines; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chromatography, Liquid; Gefitinib; Glioblastoma; Mice; Models, Biological; Quinazolines; Tandem Mass Spectrometry | 2012 |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 2012 |
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Female; Glioblastoma; Humans; Immunohistochemistry; Intermediate Filament Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Nude; Nerve Tissue Proteins; Nestin; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplastic Stem Cells; Quinazolines; Veratrum Alkaloids | 2012 |
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Furans; Gene Expression; Glioblastoma; Humans; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Glioblastoma; Humans; Male; Mice; Mice, SCID; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Protein Array Analysis; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Response to: "rare serious complications of erlotinib therapy".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Rare serious complications of erlotinib therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Cerebellum; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Phosphorylation; Placenta; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.
Topics: 3T3 Cells; Animals; Cell Adhesion; Cell Movement; Enzyme Inhibitors; ErbB Receptors; Fibroblasts; Glioblastoma; Mice; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Phospholipase C gamma; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured; Type C Phospholipases; Tyrphostins | 2004 |
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
Topics: Actins; Apoptosis; Cell Division; Cell Line, Tumor; Cell Movement; DNA Primers; DNA, Complementary; ErbB Receptors; Erlotinib Hydrochloride; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Cell Division; Cell Line; Cluster Analysis; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Nucleic Acid Hybridization; Quinazolines; Sesquiterpenes; Tumor Cells, Cultured | 2004 |
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Topics: Animals; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Swiss 3T3 Cells; Time Factors | 2004 |
Gefitinib in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results | 2004 |
Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae.
Topics: Caveolin 1; Caveolins; Cell Division; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Phosphorylation; Quinazolines; Tyrosine; Tyrphostins | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.
Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Chelating Agents; Egtazic Acid; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Oligonucleotides, Antisense; Phosphorylation; Protein Kinase C-delta; Pyrimidines; Quinazolines; Receptors, Neurokinin-1; RNA, Small Interfering; Signal Transduction; Tyrphostins | 2005 |
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Collagen; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Glioblastoma; Humans; Immunohistochemistry; In Vitro Techniques; Laminin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Proteoglycans; Quinazolines; Radiation, Ionizing; Time Factors; Vascular Endothelial Growth Factor A | 2005 |
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Immunoprecipitation; Models, Biological; Phosphoproteins; Phosphorylation; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Thymidine; TOR Serine-Threonine Kinases | 2005 |
Glioblastoma multiforme and the epidermal growth factor receptor.
Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2005 |
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction | 2005 |
Response of glioblastomas to EGFR kinase inhibitors.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2006 |
Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.
Topics: Animals; Area Under Curve; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Injections, Intravenous; Injections, Subcutaneous; Mice; Molecular Structure; Protein Tyrosine Phosphatases; Quinazolines; Rats; Thymidine; Tyrphostins; Xenograft Model Antitumor Assays | 2006 |
Gefitinib accumulation in glioblastoma tissue.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mass Spectrometry; Quinazolines | 2006 |
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Topics: Adult; Aged; Animals; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Glioblastoma; Humans; Male; Mice; Mice, Nude; Middle Aged; Quinazolines; Survival Rate; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Dose-Response Relationship, Drug; Flow Cytometry; Fluoresceins; Glioblastoma; Humans; Insecticides; Kinesins; Molecular Structure; Paclitaxel; Pyrimidines; Quinazolines; Rotenone; Spindle Apparatus; Tetrahydroisoquinolines; Thiones; Time Factors; Tubulin; Tubulin Modulators; Vinblastine | 2007 |
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transfection | 2006 |
Gefitinib concentrations in human glioblastoma tissue.
Topics: Antineoplastic Agents; Biological Availability; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Quinazolines | 2007 |
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Topics: Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Densitometry; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Indicators and Reagents; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Topotecan; Tumor Suppressor Protein p53 | 2007 |
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Topics: Animals; Astrocytes; Binding Sites; Cell Line, Tumor; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Models, Molecular; Mutation, Missense; Neoplasms, Experimental; NIH 3T3 Cells; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2006 |
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Signal Transduction; Sulfonamides | 2007 |
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Models, Biological; Mutation; Pharmacogenetics; Quinazolines; Xenograft Model Antitumor Assays | 2008 |
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspase 3; Caspases; Cisplatin; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Enzyme Precursors; ErbB Receptors; Glioblastoma; Humans; Nitriles; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Cells, Cultured; Tyrphostins | 1998 |
4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dose-Response Relationship, Drug; Epidermal Growth Factor; Glioblastoma; Humans; Mice; Mice, SCID; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
Topics: Actins; Antineoplastic Agents; Cell Adhesion; Epidermal Growth Factor; Glioblastoma; Humans; Integrins; Neoplasm Invasiveness; Quinazolines; Tumor Cells, Cultured | 1998 |
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Topics: Animals; Brain Neoplasms; Cell Survival; Cisplatin; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Protein Tyrosine Phosphatases; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrphostins | 2001 |
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Topics: Apoptosis; Arabidopsis Proteins; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Plant Proteins; Potassium Channels; Quinazolines; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2002 |
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.
Topics: Animals; Enzyme Inhibitors; ErbB Receptors; Extracellular Matrix Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Metalloendopeptidases; Mice; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases; Transfection; Tumor Cells, Cultured; Tyrphostins; Up-Regulation | 2002 |
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Topics: 3T3 Cells; Animals; Brain Neoplasms; Cell Division; Cell Survival; Glioblastoma; Humans; Ligands; Lymphokines; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2002 |